Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTPA | P49638 | 3/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11706439 | 1.00 | TTPA (0.58) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL11707766 | 1.00 | TTPA (0.58) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL2059457 | 0.88 | PTGS1 (0.66) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL11701874 | 0.88 | PTGS1 (0.66) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL11705224 | 0.88 | PTGS1 (0.66) | TTPAALOX5MEN1KMT2APDE4A | |
| Hydrochloric Acid SCHEMBL11702891 | 0.86 | PTGS1 (0.64) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL8544235 | 0.86 | TTPA (0.58) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL10346379 | 0.86 | PTGS1 (0.52) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL8538768 | 0.84 | TTPA (0.56) | TTPAALOX5MEN1KMT2APDE4A | |
| SCHEMBL10535364 | 0.83 | MEN1 (0.54) | TTPAALOX5MEN1KMT2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4003919-A | INTERMEDIATES FOR ALPHA-TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | claimed |
| EP-3733642-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3733642-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3456707-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3456707-A1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BioElectron Technology Corporation (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-8519001-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-7968746-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2220030-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009061744-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-4026907-A | INTERMEDIATES FOR ALPHA-TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-4018799-A | INTERMEDIATES FOR TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4003919-A | INTERMEDIATES FOR ALPHA-TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3947473-A | (6-HYDROXY-CHROMAN-2-YL) CARBOXYLIC ACID DERIVATIVES | HOFFMAN-LA ROCHE INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TTPA 1016/4885ALOX5 1668/4885MEN1 3606/4885 |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | TTPA 900/4885ALOX5 1820/4885MEN1 3518/4885 |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TTPA 900/4885ALOX5 1820/4885MEN1 3518/4885 |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TTPA 900/4885ALOX5 1820/4885MEN1 3518/4885 |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TTPA 900/4885ALOX5 1820/4885MEN1 3518/4885 |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | TTPA 949/4885ALOX5 1722/4885MEN1 3538/4885 |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | TTPA 1016/4885ALOX5 1668/4885MEN1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.